Nachrichten zur Regeneron Pharmaceuticals Inc. Aktie

Regeneron Pharmaceuticals, Inc. (REGN) Goldman Sachs 45th Annual Global Healthcare Conference (Transcript)

…

BRODSKY & SMITH SHAREHOLDER UPDATE: Notifying Investors of the Following Investigations: Avangrid, Inc. (NYSE - AGR), SilverBow Resources, Inc. (NYSE - SBOW), Reneo Pharmaceuticals, Inc. (Nasdaq - RPHM), Perficient, Inc. (Nasdaq - PRFT)

BALA CYNWYD, Pa., June 07, 2024 (GLOBE NEWSWIRE) -- Brodsky & Smith reminds investors of the following investigations.…

Regeneron Pharmaceuticals, Inc. (REGN) Management presents at Jefferies 2024 Global Healthcare Conference (Transcript)

…

Regeneron Pharmaceuticals: RBC Capital erhöht Kursziel - Dupixent im Fokus - Aktienanalyse

Toronto (www.aktiencheck.de) - Regeneron Pharmaceuticals-Aktienanalyse von RBC Capital Markets: Die kanadische Bank RBC Capital Markets stuft die Aktie von Regeneron Pharmaceuticals…

Minimale Kursveränderung bei Regeneron Pharmaceuticals-Aktie (893,3290 €)

CODE Zuletzt zahlten Investoren für die Aktie 968,86 US-Dollar. Wenig getan hat sich heute bislang beim Kurs von Regeneron Pharmaceuticals.…

Update on FDA Priority Review of Dupixent® (dupilumab) for the Treatment of COPD Patients with Type 2 Inflammation

TARRYTOWN, N.Y. and PARIS, May 31, 2024 (GLOBE NEWSWIRE) -- Regeneron Pharmaceuticals, Inc. (NASDAQ: REGN) and Sanofi today…

5 Biggest Pharmaceutical ETFs in 2024

The global pharmaceutical market reached a total value of US$1.6 trillion in 2023, according to Statista, up significantly from the…

Bragar Eagel & Squire, P.C. Is Investigating Zymeworks, Regeneron, Jabil, and DoubleVerify and Encourages Investors to Contact the Firm

NEW YORK, May 19, 2024 (GLOBE NEWSWIRE) -- Bragar Eagel & Squire, P.C., a nationally recognized shareholder rights…

Regeneron Pharmaceuticals Inc (REGN) RBC Capital Markets Global Healthcare Conference (Transcript)

…

Regeneron Pharmaceuticals: Evercore ISI nimmt Coverage auf - Aktienanalyse

New York (www.aktiencheck.de) - Regeneron Pharmaceuticals-Aktienanalyse von Evercore ISI: Die Analysten von Evercore ISI nehmen die Coverage für die Aktie von…

Reneo Pharmaceuticals and OnKure Announce Proposed Merger

Merger to create a Nasdaq-listed, clinical-stage biopharmaceutical company focused on advancing OnKure’s portfolio of novel precision medicines in oncology…

FDA prüft Antrag von Regeneron und Sanofi für Dupixent vorrangig

Von Colin Kellaher NEW YORK (Dow Jones)--Die US-Gesundheitsbehörde FDA prüft eine Zulassungserweiterung für das entzündungshemmende Blockbuster-Medikament Dupixent von Regeneron…

Regeneron Pharmaceuticals, Inc. 2024 Q1 - Results - Earnings Call Presentation

…

Regeneron misses profit estimates on weaker Eylea and Dupixent sales

U.S. drugmaker Regeneron Pharmaceuticals Inc missed Wall Street estimates for first-quarter profit on Thursday due to softer sales of its…

Regeneron Pharmaceuticals: Kursziel gesteigert

New York (www.aktiencheck.de) - Rating-Update: Die Analysten von TD Cowen stufen die Aktie von Regeneron Pharmaceuticals Inc. (ISIN: US75886F1075, WKN: 881535,…

The Zacks Analyst Blog Highlights Danaher, Regeneron Pharmaceuticals, Palo Alto Networks, Workday and American Electric Power

Danaher, Regeneron Pharmaceuticals, Palo Alto Networks, Workday and American Electric Power are part of the Zacks top Analyst Blog.…

Top Stock Reports for Danaher, Regeneron Pharmaceuticals & Palo Alto Networks

Todays Research Daily features new research reports on 16 major stocks, including Danaher Corporation (DHR), Regeneron Pharmaceuticals, Inc. (REGN) and…

Kirby McInerney LLP Announces Investigation of Shareholder Claims Against Regeneron Pharmaceuticals, Inc. (REGN)

NEW YORK, April 18, 2024 (GLOBE NEWSWIRE) -- The law firm of Kirby McInerney LLP is investigating potential…

Regeneron Pharmaceuticals: Kursziel angehoben

Charlotte (www.aktiencheck.de) - Rating-Update: Geoff Meacham, Analyst von BofA Securities, stuft die Aktie von Regeneron Pharmaceuticals Inc. (ISIN: US75886F1075, WKN: 881535,…

Regeneron Pharmaceuticals: Kaufgelegenheit in der Underperformance - Aktienanalyse

Toronto (www.aktiencheck.de) - Regeneron Pharmaceuticals-Aktienanalyse von RBC Capital Markets: Die kanadische Bank RBC Capital Markets stuft die Aktie von Regeneron Pharmaceuticals…

Regeneron Pharma falls after US government alleges fraud

Regeneron Pharmaceuticals Inc (NASDAQ:REGN) faced a blow in pre-market trading after being hit with fraud allegations from the US Justice…

Biotech Stocks: 5 Biggest Companies in 2024

What are the top biotech companies? The following five stocks have market capitalizations worth billions of dollars and operate in…

How to Invest in Biotechnology (Updated 2024)

Investors interested in the life science sector are well aware of the importance of biotechnology.From finding cures for diseases to…

Reneo Pharmaceuticals Reports Fourth Quarter And Full Year 2023 Financial Results And Business Update

IRVINE, Calif., March 28, 2024 (GLOBE NEWSWIRE) -- Reneo Pharmaceuticals, Inc. (Nasdaq: RPHM), a pharmaceutical company historically focused…

Food Allergy Treatment Drug Market to Register Immense Growth by 2032, Assesses DelveInsight | Key Companies - Vedanta Biosciences, Novartis, Alladapt Immunotherapeutics, Regeneron Pharmaceuticals, Genentech, Parexel

The overall dynamics of the food allergy market are anticipated to change in the coming years owing to the expected…

Is Regeneron Pharmaceuticals, Inc.s (NASDAQ:REGN) Latest Stock Performance A Reflection Of Its Financial Health?

Regeneron Pharmaceuticals (NASDAQ:REGN) has had a great run on the share market with its stock up by a significant 14...…

Kuehn Law Encourages Investors of Regeneron Pharmaceuticals, Inc. to Contact Law Firm

Kuehn Law investigates potential breach of fiduciary duties by Regeneron Pharmaceuticals officers and directors. Shareholders urged to contact for details.…

Regeneron Pharmaceuticals, Inc. (REGN) Leerink Partners Global Biopharma Conference (Transcript)

…

Regeneron Pharmaceuticals: Morgan Stanley erhöht Kursziel auf 1.115 USD - Aktienanalyse

New York (www.aktiencheck.de) - Regeneron Pharmaceuticals-Aktienanalyse von Morgan Stanley: Die Analysten von Morgan Stanley stufen die Aktie von Regeneron Pharmaceuticals Inc.…

Regeneron Pharmaceuticals, Inc. (REGN) Management Presents at Barclays 26th Annual Global Healthcare Conference (Transcript)

…

Regeneron Pharmaceuticals: Neue Coverage

New York (www.aktiencheck.de) - Rating-Update: William Pickering, Analyst von Sanford C. Bernstein & Co, nimmt die Coverage der Aktie von Regeneron…

5 Small Biotech ETFs to Watch (Updated 2024)

Thanks to exchange-traded funds (ETFs), investors don’t have to be tied to one specific stock. Biotech ETFs allow market participants…

Regeneron Pharmaceuticals, Inc. (REGN) TD Cowen 44th Annual Health Care Conference Call Transcript

…

Regeneron Pharmaceuticals: Kursziel gesteigert

Toronto (www.aktiencheck.de) - Rating-Update: Die Analysten von RBC Capital Markets stufen die Aktie von Regeneron Pharmaceuticals Inc. (ISIN: US75886F1075, WKN: 881535,…

Regeneron Pharmaceuticals: Kursziel erhöht

New York (www.aktiencheck.de) - Rating-Update: Die Analysten von Argus Research stufen die Aktie von Regeneron Pharmaceuticals Inc. (ISIN: US75886F1075, WKN: 881535,…

Regeneron Pharmaceuticals, Inc. (REGN) Oppenheimer 34th Annual Healthcare Life Sciences Conference (Transcript)

…

Regeneron Pharmaceuticals: Time To Change My Strategy After Encouraging Q4 2024

…

Regeneron Pharmaceuticals, Inc. (REGN) Q4 2023 Earnings Call Transcript

…

Regeneron Pharmaceuticals, Inc. 2023 Q4 - Results - Earnings Call Presentation

…

Regeneron Pharmaceuticals: Starke Quartalszahlen sorgen für ein sattes Kursplus - Unbedingt dabeibleiben! Aktienanalyse

Kulmbach (www.aktiencheck.de) - Regeneron Pharmaceuticals-Aktienanalyse von "Der Aktionär": Michel Doepke vom Anlegermagazin "Der Aktionär" nimmt die Aktie von Regeneron Pharmaceuticals Inc.…

AKTIONÄR-Top-Tipp Regeneron: Bockstarke Zahlen – magische Marke geknackt

Noch nie stand die Aktie von Regeneron Pharmaceuticals über der magische Marke von 1.000,00 Dollar. Am Freitag dieser Handelswoche notiert…

Regeneron Pharmaceuticals beats top-line and bottom-line estimates; initiates FY24 outlook

…

Regeneron Reports Fourth Quarter and Full Year 2023 Financial and Operating Results

TARRYTOWN, N.Y., Feb. 02, 2024 (GLOBE NEWSWIRE) -- Regeneron Pharmaceuticals, Inc. (NASDAQ: REGN) today announced financial results for…

Linvoseltamab Receives EMA Filing Acceptance for Treatment of Relapsed/Refractory Multiple Myeloma

TARRYTOWN, N.Y., Feb. 02, 2024 (GLOBE NEWSWIRE) -- Regeneron Pharmaceuticals, Inc. (NASDAQ: REGN) today announced that the European Medicines Agency…

Melanoma Drugs - $13.98 Billion Industry Opportunity Assessment, 2024-2028: Regional Insights and Competitor Market Shares

Dublin, Jan. 24, 2024 (GLOBE NEWSWIRE) -- The "Melanoma Drugs Global Market Report 2024" report has been added…

dpa-AFX ProFeed